Federal scientific center for research and development of immunological products to them. M. P. Chumakov intends by early August of this year to complete preclinical studies of their own vaccines against coronavirus infection. Clinical studies will be completed in January 2021, told TASS General Director of the center Chumakov, corresponding member of RAS Aydar Ishmukhametov.
“Our center is working to create televizionnoi inactivated vaccine against coronavirus. From our point of view, so the vaccine is correct, first, because there is no evidence as which parts of the virus to use correctly, and secondly, the technology for creating vaccines consist of whole have long been developed and successfully used for several decades. Planned for early August to complete preclinical trials of its own vaccine, and in January 2021 after successful completion of clinical trials we can talk about large-scale production of vaccines, for which we have our own production”, – he said.
In the vaccines consist of whole used or artificially weakened and therefore unable to cause disease viruses viruses are already killed (inactivated).
“I think quick fixes to create vaccines much unjustified. Before the vaccine to market, it is necessary to conduct its most serious test,” – said Ishmukhametov. He noted that the issue of the variability of the coronavirus is not entirely clear. “Rather, its evolution may wear uneven, but not by type of influenza, what you love to compare,” he added.